Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.38 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | PDE4A | P27815 | 3/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25937211 | 0.86 | DRD2 (0.36) | ALDH1A1PDE4DCA9KMT2AHCRTR1 | |
| SCHEMBL25937383 | 0.80 | DRD2 (0.37) | RORCPDE4DCYP19A1DRD2PDE4A | |
| SCHEMBL24978461 | 0.78 | CACNB4 (0.42) | TAS1R3TAS1R1TAS1R2KMT2ADRD2 | |
| SCHEMBL14416606 | 0.76 | ALDH1A1 (0.59) | TAS1R3TAS1R1TAS1R2KDM4EALDH1A1 | |
| SCHEMBL24977573 | 0.70 | CACNB4 (0.41) | TAS1R3TAS1R1TAS1R2KMT2ADRD2 | |
| SCHEMBL9146354 | 0.70 | CXCR2 (0.36) | TAS1R3TAS1R1TAS1R2RORCCYP19A1 | |
| SCHEMBL20855780 | 0.67 | CYP3A4 (0.47) | KDM4EALDH1A1HSD17B10CA9KMT2A | |
| SCHEMBL20855913 | 0.67 | SMN1; SMN2 (0.48) | KDM4EALDH1A1HSD17B10CA9KMT2A | |
| SCHEMBL25937250 | 0.66 | MCHR1 (0.40) | CYP19A1 | |
| SCHEMBL10497869 | 0.66 | CA9 (0.51) | KDM4EALDH1A1CA9KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310423-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11707462-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | BOUNDLESS BIO, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310423-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | CHEK1, CHEK2, RAD1 | TAS1R3 3581/4885TAS1R1 3442/4885TAS1R2 3720/4885 |
| US-11707462-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | CHEK1, CHEK2, RAD1 | TAS1R3 3581/4885TAS1R1 3442/4885TAS1R2 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.